Critics of co-pay coupons allege these payments allow branded manufacturers to circumvent incentives to encourage the use of lower-cost alternatives. With increased use of these coupons, as well as several high-profile cases in the courts, it is timely to explore the economic effects of co-pay coupons and consider a framework for assessing their impact. Click the link below to read more.
Upper Payment Limits (UPLs) explained
Regulatory shifts create new challenges for pharmaceutical stakeholders. Four states now have PDABs empowered to set UPLs for public payers, and three states...